|
Breast cancer subtypes
|
RFS
|
OS
|
DMFS
|
|---|
|
HR
|
95% CI
|
P-value
|
HR
|
95% CI
|
P-value
|
HR
|
95% CI
|
P-value
|
|---|
|
ER status
|
|
ER+
|
1.85
|
1.57–2.18
|
< 0.001
|
2.61
|
1.86–3.68
|
< 0.001
|
2.92
|
2.09–4.07
|
< 0.001
|
|
ER-
|
1.18
|
0.9–1.18
|
0.23
|
1.24
|
0.8–1.92
|
0.34
|
1.4
|
0.9–2.17
|
0.13
|
|
PR status
|
|
PR+
|
3.4
|
2.09–5.55
|
< 0.001
|
6.34
|
1.26–31.88
|
ns, 0.011
|
3.92
|
1.15–13.32
|
ns, 0.018
|
|
PR-
|
1.51
|
1.11–2.05
|
ns, 0.0081
|
2.79
|
0.99–7.82
|
ns, 0.042
|
3.39
|
1.88–6.11
|
< 0.001
|
|
HER2 status
|
|
HER2+
|
1.73
|
1.17–2.56
|
ns, 0.0053
|
3.42
|
1.52–7.72
|
0.0017
|
1.78
|
0.94–3.39
|
ns, 0.073
|
|
HER2-
|
2.12
|
1.79–2.51
|
< 0.001
|
1.7
|
1.37–2.12
|
< 0.001
|
1.93
|
1.58–2.36
|
< 0.001
|
|
Lymph node status
|
|
Lymph node+
|
2.19
|
1.67–2.88
|
< 0.001
|
1.72
|
1.18–2.5
|
ns, 0.0044
|
2.03
|
1.4–2.94
|
< 0.001
|
|
Lymph node-
|
1.82
|
1.52–2.17
|
< 0.001
|
3
|
1.88–4.78
|
< 0.001
|
2.39
|
1.8–3.19
|
< 0.001
|
|
Grade
|
|
1
|
3.12
|
1.8–5.42
|
< 0.001
|
3.19
|
1.28–7.96
|
ns, 0.0087
|
2.79
|
1.23–6.33
|
ns, 0.011
|
|
2
|
1.99
|
1.56–2.55
|
< 0.001
|
2.55
|
1.67–3.89
|
< 0.001
|
2.61
|
1.85–3.68
|
< 0.001
|
|
3
|
1.35
|
1.07–1.7
|
ns, 0.011
|
1.25
|
0.89–1.77
|
0.19
|
1.75
|
1.13–2.73
|
ns, 0.012
|
|
TP53 status
|
|
Mutated
|
0.77
|
0.48–1.26
|
0.3
|
0.69
|
0.34–1.42
|
0.32
|
0.56
|
0.26–1.22
|
0.14
|
|
Wild type
|
1.82
|
1.16–2.85
|
ns, 0.0077
|
2.56
|
1.38–4.76
|
0.0021
|
3.67
|
1.76–7.63
|
< 0.001
|
- ns Not significant after correction for multiple hypothesis testing; bold faced: remained significant
